Could cause temporary or reversible harm; serious harm is unlikely.
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
| Brand name | GANIRELIX ACETATE |
| Generic name | GANIRELIX ACETATE |
| Active ingredient(s) | GANIRELIX ACETATE |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States |
| NDC | 70748-274-01 |
| Full product label | Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | FL, MA, MI & OH |
| Quantity | 32736 vials |
| Recall initiated | 2025-11-13 |
| Report date | 2025-12-17 |
| Recall completed | — |
| Recall number | D-0220-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Naples FL United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗